Therapy in hidradenitis suppurativa

There is currently an unmet need for new treatments for hidradenitis suppurativa (HS)

The authors of this prospective, randomised, double-blind, placebo-controlled study in Denmark investigated the efficacy of adalimumab in the treatment of HS. Twenty-one patients were randomised two to one to active treatment with adalimumab 80mg subcutaneously at baseline followed by 40mg subcutaneously every other week for 12 weeks (n = 15) or placebo (n = 6).

After six weeks, a significant reduction in severity of HS was seen and after 12 weeks, the reduction was almost significant. Adalimumab therefore reduces the severity of HS and improves quality of life in patients with this chronic inflammatory disease, the researchers say.
Miller I, Lynggaard CD, Lophaven S et al. Br J Dermatol 2011; 165: 391-8

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

PHE issues coronavirus guidance for primary care

PHE issues coronavirus guidance for primary care

Public Health England (PHE) has issued guidance for...

HPV infections fall dramatically but researchers say vaccine efficacy is 'uncertain'

HPV infections fall dramatically but researchers say vaccine efficacy is 'uncertain'

Cancer-causing HPV16 and 18 infections are now 'extremely...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Drug shortages - live tracker

Drug shortages - live tracker

Added: Adcal D3 Dissolve, Diamox SR, flumetasone/clioquinol,...